StockData
Palvella Therapeutics, Inc. logo

Palvella Therapeutics, Inc. (PVLA) stock

PVLANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$144.35−0.25 (-0.17%)

Close on Nov 17, 2026Market cap $2.08BP/E –Yield –

Palvella Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Palvella Therapeutics's profit margin for the twelve months ending Sep 30, 2024 was 1861.5%. For fiscal 2023 it was 43.7%, against -128.5% the year before. The highest annual figure on record is 43.7% in fiscal 2023.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2023Dec 31, 202343.7%+172.1
FY2022Dec 31, 2022-128.5%+17.1
FY2021Dec 31, 2021-145.6%−18.6
FY2020Dec 31, 2020-127.0%−71.9
FY2019Dec 31, 2019-55.0%+36.9
FY2018Dec 31, 2018-91.9%−22.1
FY2017Dec 31, 2017-69.8%+321.2
FY2016Dec 31, 2016-391.0%+88.5
FY2015Dec 31, 2015-479.5%−295.9
FY2014Dec 31, 2014-183.6%−184.1
FY2013Dec 31, 20130.5%–

Quarterly profit margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q1 FY2024Mar 31, 2024-4784.9%−4104.0
Q4 FY2023Dec 31, 20232975.4%+3114.0
Q3 FY2023Sep 30, 2023-55.1%+126.2
Q2 FY2023Jun 30, 202319.8%+299.4
Q1 FY2023Mar 31, 2023-680.9%−634.5
Q4 FY2022Dec 31, 2022-138.6%−25.7
Q3 FY2022Sep 30, 2022-181.3%+226.3
Q2 FY2022Jun 30, 2022-279.6%+192.2
Q1 FY2022Mar 31, 2022-46.4%−19.7
Q4 FY2021Dec 31, 2021-112.9%+654.3
Q3 FY2021Sep 30, 2021-407.6%+78.4
Q2 FY2021Jun 30, 2021-471.8%−427.8
Q1 FY2021Mar 31, 2021-26.7%+0.4
Q4 FY2020Dec 31, 2020-767.2%−762.7
Q3 FY2020Sep 30, 2020-486.0%−468.9
Q2 FY2020Jun 30, 2020-44.0%+176.5
Q1 FY2020Mar 31, 2020-27.1%+94.0
Q4 FY2019Dec 31, 2019-4.5%+233.3
Q3 FY2019Sep 30, 2019-17.1%+56.6
Q2 FY2019Jun 30, 2019-220.5%−218.8
Q1 FY2019Mar 31, 2019-121.1%+88.8
Q4 FY2018Dec 31, 2018-237.7%−279.0
Q3 FY2018Sep 30, 2018-73.7%+106.0
Q2 FY2018Jun 30, 2018-1.7%+542.5
Q1 FY2018Mar 31, 2018-209.9%+385.4
Q4 FY2017Dec 31, 201741.3%+281.8
Q3 FY2017Sep 30, 2017-179.8%+609.6
Q2 FY2017Jun 30, 2017-544.3%–
Q1 FY2017Mar 31, 2017-595.2%–
Q4 FY2016Dec 31, 2016-240.5%–
Q3 FY2016Sep 30, 2016-789.3%–

More Palvella Therapeutics figures

See a number that looks wrong?